Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
as soon as is submitted to ZB.
Targeted molecular therapeutics for pulmonary diseases: Addressing the need for precise drug delivery.
In:. Berlin ; Heidelberg: Springer, 2024. DOI: 10.1007/164_2023_703 (Handb. Exp. Pharmacol.)
Respiratory diseases are a major concern in public health, impacting a large population worldwide. Despite the availability of therapies that alleviate symptoms, selectively addressing the critical points of pathopathways remains a major challenge. Innovative formulations designed for reaching these targets within the airways, enhanced selectivity, and prolonged therapeutic effects offer promising solutions. To provide insights into the specific medical requirements of chronic respiratory diseases, the initial focus of this chapter is directed on lung physiology, emphasizing the significance of lung barriers. Current treatments involving small molecules and the potential of gene therapy are also discussed. Additionally, we will explore targeting approaches, with a particular emphasis on nanoparticles, comparing targeted and non-targeted formulations for pulmonary administration. Finally, the potential of inhaled sphingolipids in the context of respiratory diseases is briefly discussed, highlighting their promising prospects in the field.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Edited volume or book chapter
Keywords
Gene Therapy ; Inhalation ; Pulmonary Administration ; Sphingolipids ; Targeted Nanoparticles
ISSN (print) / ISBN
0171-2004
Publisher
Springer
Publishing Place
Berlin ; Heidelberg
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Lung Health and Immunity (LHI)